The developability classification system: application of biopharmaceutics concepts to formulation development.
A revised classification system for oral drugs was developed using the biopharmaceutics classification system (BCS) as a starting point. The revised system is designed to have a greater focus on drug developability. Intestinal solubility, the compensatory nature of solubility and permeability in the small intestine and an estimate of the particle size needed to overcome dissolution rate limited absorption were all considered in the revised system. The system was then validated by comparison with literature on the in vivo performance of a number of test compounds. Observations on the test compounds were consistent with the revised classification, termed the developability classification system (DCS), showing it to be of greater value in predicting what factors are critical to in vivo performance than the widely used BCS.
Butler
James M
JM
Pharmaceutical Development, GlaxoSmithKline R&D, Harlow, UK. james.m.butler@gsk.com
Dressman
Jennifer B
JB
D000042:Absorption; D000284:Administration, Oral; D001702:Biopharmaceutics / Q000379:methods*; D002626:Chemistry, Pharmaceutical; D006801:Humans; D008954:Models, Biological; D010316:Particle Size; D010539:Permeability; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000145:classification* / Q000378:metabolism; D010599:Pharmacokinetics; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D012995:Solubility
D004364:Pharmaceutical Preparations